MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
Bristol-Myers Squibb
Study ID
NCT00112580
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Biological therapies, such as MDX-010, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well MDX-010 works in treating patients with stage IV pancreatic cancer that cannot be removed by surgery.

Key Dates

Start date
Jul 31, 2005
Status verified
Sep 2021
Primary completion
Jun 30, 2009
Completion
Jun 30, 2009

Study Design

Enrollment
27 participants (actual)
Primary purpose
TREATMENT

Primary Outcome Measure

Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [ Time Frame: From first dose to 3 weeks following the end of the treatment cycle, up to 24 weeks. ]

Locations (2)

FacilityCityStateZIPSite coordinators
NCI - Surgery BranchBethesdaMaryland20892-
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral OfficeBethesdaMaryland20892-1182-

Find similar trials in Bethesda, MD

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
NCI - Surgery Branch· Bethesda, MDWarren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office· Bethesda, MD

Related Studies